5-(4-trifluoromethyl-phenyl)pyridin-2-ylamine | 893738-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(4-trifluoromethyl-phenyl)pyridin-2-ylamine
• 英文别名: 5-[4-(Trifluoromethyl)phenyl]-2-pyridinamine；5-[4-(trifluoromethyl)phenyl]pyridin-2-amine
• CAS: 893738-30-2
• 化学式: C₁₂H₉F₃N₂
• mdl: MFCD06802143
• 分子量: 238.212
• InChiKey: ILBDUGQRPWLKIR-UHFFFAOYSA-N

物化性质

• 沸点：
  314.2±37.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-(4-trifluoromethyl-phenyl)pyridin-2-ylamine 、 苯甲酰氯 在 吡啶 作用下， 反应 2.0h， 以52%的产率得到N-{5-[4-(trifluoromethyl)phenyl]pyridin-2-yl}benzamide
  参考文献：
  名称：

  False Positives in a Reporter Gene Assay: Identification and Synthesis of Substituted N-Pyridin-2-ylbenzamides as Competitive Inhibitors of Firefly Luciferase

  摘要：

  Luciferase reporter-gene assays are a commonly used technique in high-throughput screening campaigns. In this study, we report on a luciferase inhibitor (1), which emerged from an antagonistic G protein-coupled receptor luciferase reporter-gene assay screen. Instead of displaying receptor activity, compound I was shown to potently inhibit luciferase in an in vitro enzymatic assay with an IC50 value of 1.7 +/- 0.1 mu M. In addition, 1 was a competitive inhibitor with respect to the substrate luciferin. A database search yielded another inhibitor (3) with a similar N-pyridin-2-ylbenzamide core. Subsequently, several analogues were prepared to investigate the structure-activity relationships of these luciferase inhibitors. This yielded the most potent inhibitor of this series (6) with an IC50 value of 0.069 +/- 0.01 mu M. Further molecular modeling studies suggested that 6 can be accommodated in the luciferin binding site. This paper is meant to alert users of luciferase reporter-gene assays for possible false positive hits including highly "druglike" molecules due to direct luciferase inhibition.

  DOI：

  10.1021/jm8004509
• 作为产物：
  描述：

  2-氨基-5-溴吡啶 、 4-三氟甲基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 5-(4-trifluoromethyl-phenyl)pyridin-2-ylamine
  参考文献：
  名称：

  新型吡啶连接咪唑并[1,2-a]吡啶衍生物的设计、合成、体外α-葡萄糖苷酶抑制、抗氧化活性和分子对接研究

  摘要：

  设计并通过Suzuki 偶联和缩合反应分两步合成了一系列新型 2-(pyridin-2-yl) H-咪唑并[1,2 - a ]吡啶衍生物，具有广泛的底物范围和良好的收率。使用不同的光谱技术表征合成化合物的结构。此外，研究了它们对α-葡萄糖苷酶的抑制活性。在各种合成的 2-(pyridin-2-yl) H - imidazo[1,2 - a ]pyridines 中，化合物5 g表现出最好的抑制效力，IC 50值为 3.7 μM，是标准抑制剂阿卡波糖的 18 倍（集成电路50  = 67.4 微米）。这些化合物的抗氧化活性通过使用体外2-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) 和 2,2-diphenyl-1-picrylhydrazyl (DPPH) 自由基生物测定来评估。进行分子对接以建立与靶酶的相互作用，这也证实了体

  DOI：

  10.1016/j.molstruc.2022.134238

文献信息

• Acetylenyl-pyrazolo-pyrimidine derivatives
  申请人：McArthur Gatti Silvia

  公开号：US20060217387A1

  公开（公告）日：2006-09-28

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

  本发明涉及式(I)的化合物：其中R1到R3、A、M、L、E、G和J的定义如描述和索赔中所述。该发明还涉及一种制备此类化合物的方法、含有它们的药物组合物，以及治疗中枢神经系统疾病的方法。
• Novel compounds as metabotropic glutamate receptor antagonists
  申请人：McArthur Gatti Silvia

  公开号：US20070072879A1

  公开（公告）日：2007-03-29

  The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R 1 , R 2 , and R 3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.

  本发明涉及具有以下结构的化合物（I）其中A、E、G、J、L、M、R1、R2和R3如规范和索赔中所定义。该发明还涉及含有这种化合物的药物组合物以及制备这些化合物和组合物的方法。这些化合物是代谢型谷氨酸受体拮抗剂，可用于治疗各种中枢神经系统疾病。
• ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES
  申请人：Gatti McArthur Silvia

  公开号：US20080300250A1

  公开（公告）日：2008-12-04

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

  本发明涉及式(I)的化合物： 其中R1至R3，A，M，L，E，G和J如描述和索赔中所定义。本发明还涉及制备这种化合物的方法，含有这些化合物的药物组合物以及治疗中枢神经系统疾病的方法。
• Compounds as metabotropic glutamate receptor antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07504404B2

  公开（公告）日：2009-03-17

  The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.

  本发明涉及式（I）的化合物，其中A、E、G、J、L、M、R1、R2和R3如说明书和权利要求所定义。本发明还涉及含有这种化合物的制药组合物和制备这种化合物及组合物的方法。这些化合物是代谢型谷氨酸受体拮抗剂，可用于治疗多种中枢神经系统疾病。
• SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS
  申请人：Gatti McArthur Silvia

  公开号：US20120041002A1

  公开（公告）日：2012-02-16

  The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R 1 , R 2 , and R 3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.

  本发明涉及式（I）的化合物，其中A，E，G，J，L，M，R1，R2和R3如规范和权利要求中所定义。该发明还涉及含有这种化合物的药物组合物以及制备这种化合物和组合物的方法。这些化合物是代谢型谷氨酸受体拮抗剂，可用于治疗多种中枢神经系统疾病。